1 / 23

FDA and Pharmaceutical Manufacturing Research Projects Jeffrey T. Macher Jackson A. Nickerson Co-Principal Investigator

FDA and Pharmaceutical Manufacturing Research Projects Jeffrey T. Macher Jackson A. Nickerson Co-Principal Investigators July 21, 2004. Presentation Overview. FDA Research Project status report History Project Goals Approach and Expected Outcomes Current Status

ellery
Download Presentation

FDA and Pharmaceutical Manufacturing Research Projects Jeffrey T. Macher Jackson A. Nickerson Co-Principal Investigator

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. FDA and Pharmaceutical Manufacturing Research ProjectsJeffrey T. Macher Jackson A. NickersonCo-Principal Investigators July 21, 2004

  2. Presentation Overview • FDA Research Project status report • History • Project Goals • Approach and Expected Outcomes • Current Status • Pharmaceutical Manufacturing Research Project (PMRP) status report • History • Project Goals • Approach and Expected Outcomes • Current Status

  3. FDA Research Project

  4. FDA Research Project History • Research project idea emerged in Fall, 2001. • Observed significant increases in both number and severity of cGMP violations. • Approached FDA in Spring, 2002. • Dozens of meetings with CBER, CDER, ORA and district offices. • Formalized relationship with FDA in Fall, 2003. • Signed Material Transfer Agreement (MTA) in October, 2003.

  5. FDA Research Project Goals • Risk-based assessment of FDA cGMP outcomes. • Identify attributes (currently recorded by the FDA) that impact inspection outcomes. • Transfer “learning” to FDA.

  6. FDA Project Approach • Compile and link FDA databases. • Estimate the likelihood of various outcomes: • NAI, VAI, OAI; Warning Letters; Field Alerts; Product Recalls. • based on… • compound/product, facility, firm, FDA district, investigator and training derived factors. • in order to … • evaluate the allocation of investigational resources. • inform effectiveness of investigator training and management.

  7. FDA Databases • COMIS (Supplement filings) • DQRS (Field alerts) • EES (Outsourcing) • FACTS (Inspections) • Product Listing • Product Recalls • Product Shortages • Registration • Warning letters • Training

  8. FDA-related Performance Outcomes • Inspection outcomes: • NAI • VAI • OAI • Warning letters • Field reports • Product recalls • Product availability

  9. FDA-related Key Factors • Product-level and Process-level variables • NDA/ANDA. • Prescription/non-prescription. • Product class. • Product subclass. • Process indicator code. • Supplement history. • Extent of vertical integration. • History of regulatory outcomes for the product. • History of regulatory actions for related products.

  10. FDA-related Key Factors • Facility-level variables • Age and Size. • Number of products produced. • Diversity of products produced: • Prescription/non-prescription; Product class; Product subclass; Process indicator code. • Increases/decreases in number of products and diversity of production n years prior. • Time since last ownership change. • Regulatory history (e.g., inspectional outcomes, warning letters and type).

  11. FDA-related Key Factors • Firm-level variables • Age and Size. • Number of manufacturing locations. • Number of products produced. • Diversity of products produced. • Number of products introduced in past n years. • Number of NAI, VAI, and OAI at non-focal facilities in the past n years. • Number and type of warning letters at non-focal facilities in the past n years.

  12. FDA-related Key Factors • FDA related variables • FDA District Identifier and annual allocated inspection hours. • Inspections • Length of cGMP inspection; Number of investigators; Reason for inspection; Time since last inspection. • Investigators • Annual experience of Pharma versus non-Pharma inspections. • Training: number and frequency of formal training classes. • Policy shifts (e.g., SUPACs)

  13. Expected Outcomes of Analysis • Statistical analysis will estimate the probability of various outcomes based on counterfactuals. • Counterfactual analysis allows a risk-based assessment of changes in at least some FDA-related oversight policies. • Results will improve understanding of certain inspection outcomes based on attributes examined. • Risk assessments (in terms of increasing probability of occurrence) will be used to: • Inform oversight choices of FDA. • Identify underlying quality of manufacturers’ production and regulatory processes.

  14. Status of FDA Research Project • Phase 1: Exploratory pilot study. • Completed Summer 2003. • Phase 2: Data collection • Complete for CDER and awaiting transfer. • Incomplete for CBER. • Phase 3: Data analysis • Awaiting transfer of data. • Analysis will require 3-6 months.

  15. Pharmaceutical Manufacturing Research Project (PMRP)

  16. PMRP Project History • Research project idea emerged in Fall, 2001. • Explore whether cGMP violations related to managerial, organizational and technical practices. • Attempt to translate lessons learned from similar research study of manufacturing in semiconductor industry. • Began interviewing manufacturers in Spring, 2002. • Dozens of interviews with pharmaceutical, biotechnology, API, and contract manufacturers. • Launched internet-based questionnaire in Fall, 2003. • Went live in November, 2003. • Ongoing marketing and participation solicitation since. • Expect to close first round of survey shortly.

  17. PMRP Goals • Develop standard set of benchmarks for measuring manufacturing and regulatory performance. • Identify managerial, organizational, and technical practices underlying manufacturing and regulatory performance. • Provide confidential “scorecard” to manufacturing facilities on how they perform against anonymous others.

  18. PMRP Approach • Develop focused questionnaire of potential factors that influence manufacturing and regulatory performance. • Administer questionnaire over internet on secure-site. • Analyze data collected using a variety of econometric techniques. • Provide summary of findings and facility scorecard to participating manufacturers.

  19. PMRP Database • Secured participation from cross section of U.S. and EU manufacturers. • 21 firms. • 60 manufacturing facilities. • Online survey with each manufacturing facility providing detailed data on between 1 and 5 compounds.

  20. PMRP Performance Outcomes • Manufacturing Performance • Theoretical / Actual yield. • Batches started / failed. • Cycle time. • Regulatory Performance. • Field alerts/Biologic deviation reports. • Warning letters. • Consent decrees. • Deviations. • Supplement approval.

  21. PMRP-related Key Factors • Company / SBU • Financial information. • Demographic information. • Manufacturing Facility • Financial information. • Demographic information (size, location, age, employees, etc.). • Product information (number, type, etc.). • Regulatory inspection information. • Extent of Outsourcing (development, manufacturing, APIs, etc.).

  22. PMRP-related Key Factors • Product and Process Development • Location. • Organization. • Timing. • Human Resource Management • Appraisal, Promotion, Mobility, Demographics, Training, etc. • Extent and use of teams. • Deviation and Supplement Management • Extent and use of information technology. • Extent and use of Process Analytic Technology (PAT). • Organization.

  23. Status of PMRP Project • Phase 1: Exploratory pilot study • Completed Summer, 2003. • Phase 2: Data collection • First round concluding shortly. • Phase 3: Data analysis • Analysis will require 3-6 months. • Statistical and econometric analysis of data. • Final reports.

More Related